Synthesis, anti-proliferative evaluation, DFT, in silico ADME and molecular modeling studies of novel imidazolones as potential EGFR inhibitors
Mohamed H Hekal, Mohamed Abdel-Megid, Mostafa E Salem, Saad Alrashdi, Abdullah Y A Alzahrani, Fatma S M Abu El-Azm · 2026
Read Synthesis, anti-proliferative evaluation, DFT, in silico ADME and molecular modeling studies of novel imidazolones as potential EGFR inhibitors by Mohamed H Hekal, Mohamed Abdel-Megid, Mostafa E Salem, Saad Alrashdi, Abdullah Y A Alzahrani, Fatma S M Abu El-Azm (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13618069.txt.
Description
Mohamed H. Hekal and five colleagues synthesize a family of bromophenyl imidazolone compounds and test them as possible cancer drugs aimed at the epidermal growth factor receptor, a well-known oncology target. Starting from a brominated oxazolone building block, they reacted it with various nitrogen partners to build the series. Lab tests measured growth inhibition in liver, breast, and colon cancer cell lines alongside normal fibroblasts for safety contrast.
One derivative, a carboethoxy-substituted compound labeled 5, stood out, halting the three cancer lines at concentrations between about seven and twelve micromolar. It spared normal cells with a selectivity index around seven, markedly better than the standard drug doxorubicin on that measure. Computer models suggested most derivatives should absorb well as oral drugs, and docking placed compound 5 snugly in the receptor's kinase pocket. The authors name these imidazolones as promising anticancer leads.
Catalog record
| CREATOR | Mohamed H Hekal, Mohamed Abdel-Megid, Mostafa E Salem, Saad Alrashdi, Abdullah Y A Alzahrani, Fatma S M Abu El-Azm |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| LICENSE | https://creativecommons.org/licenses/by/3.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |